Pfizer launches online pipeline tracker
pharmafile | December 21, 2006 | News story | Sales and Marketing |Â Â Â
Pfizer has launched a new online service which provides detailed insight into its R&D pipeline.
The company is taking a lead in the industry in making its pipeline more transparent, and will satisfy investors, who increasingly demand transparency in pharma R&D portfolios.
Pfizer will update its online R&D overview twice a year, making it one of the most accurate published pipelines in the industry.
"Today's posting will provide investors as well as the scientific and medical communities with more detail on our pipeline than ever before, as well as the ability to see updates on our progress," said Dr. John LaMattina, president of Pfizer Global Research and Development.
"We have the largest and most diverse pipeline in our history. One of our most important business priorities is bringing these compounds forward so that they reach the patients who need them and drive our long-term growth. We have set specific and realistic goals for introducing a steady stream of new products in the years ahead – four internally developed products by 2011 plus two externally acquired products by 2010 – and we look forward to reporting on our progress."
The company was dealt a major blow in early December when it was forced to cancel its next blockbuster-in-waiting, cholesterol drug torcetrapib, because of safety problems.
Despite the setback, Pfizer is expected to retain its number one position in the industry by combining in-licensed compounds with drugs developed in-house.
There are nearly 250 pre-clinical and clinical programmes in its pipeline, including 169 new molecular entities.
Descriptions of Pfizer's 11 major therapeutic areas and 63 top-priority diseases are also provided on the new website.
The new site provides details of Pfizer's largest-ever pipeline and innovative research in cancer, heart disease, diabetes, neurological and infectious diseases, and many other disease areas.
The site includes clinical programmes from phase I compounds to late-stage medicines under regulatory review plus recently-approved products.
